Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.

Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S

Open source

DOI: 10.1016/s1470-2045(24)00673-9
Published: 2024 Dec
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-24-00673-9,
  title = {Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.},
  author = {Rugo HS and Lerebours F and Ciruelos E and Drullinsky P and Ruiz-Borrego M and Neven P and Park YH and Prat A and Bachelot T and Juric D and Turner N and Sophos N and Zarate JP and Arce C and Shen YM and Turner S and Kanakamedala H and Hsu WC and Chia S},
  year = {2024},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(24)00673-9},
  url = {https://doi.org/10.1016/s1470-2045(24)00673-9}
}

RIS

TY  - JOUR
TI  - Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
AU  - Rugo HS
AU  - Lerebours F
AU  - Ciruelos E
AU  - Drullinsky P
AU  - Ruiz-Borrego M
AU  - Neven P
AU  - Park YH
AU  - Prat A
AU  - Bachelot T
AU  - Juric D
AU  - Turner N
AU  - Sophos N
AU  - Zarate JP
AU  - Arce C
AU  - Shen YM
AU  - Turner S
AU  - Kanakamedala H
AU  - Hsu WC
AU  - Chia S
PY  - 2024
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(24)00673-9
UR  - https://doi.org/10.1016/s1470-2045(24)00673-9
ER  -

APA

HS, R., F, L., E, C., P, D., M, R., P, N., YH, P., A, P., T, B., D, J., N, T., N, S., JP, Z., C, A., YM, S., S, T., H, K., WC, H., & S, C. (2024). Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(24)00673-9

Source records

pubmed · retrieved 2026-11-10T13:35:41.082Z